Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DG3173 MAD Study in Healthy Volunteers
NCT02217839Phase 1Completed
- Sponsor
- Aspireo Pharmaceuticals Ltd.
- Start
- Apr 2012
- Primary completion
- Jan 2013
- Modality
- Peptides, Recombinant Proteins and Enzymes
01
Overview
Phase 1, randomised, double-blind trial of veldoreotide in acromegaly (2 arms), sponsored by Aspireo Pharmaceuticals Ltd. Primary endpoints: Number of serious adverse events or withdrawals due to adverse events at 10 days, Laboratory investigations (biochemistry, hematology, urinalysis) at 10 days and 2 more. Started Apr 2012; status: completed.
02
Drugs
veldoreotide
03
Conditions
acromegaly
Beyond the preview
Go deeper on NCT02217839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02217839.